Literature DB >> 7616116

Structural and functional differences of subspecies of apoA-I-containing lipoprotein in patients with plasma cholesteryl ester transfer protein deficiency.

T Ohta1, R Nakamura, K Takata, Y Saito, S Yamashita, S Horiuchi, I Matsuda.   

Abstract

ApoA-I-containing lipoproteins exist in plasma in two main forms: one contains only apoA-I (LpA-I) while the other contains both apoA-I and apoA-II (LpA-I/A-II). We characterized structural and functional changes of these lipoproteins in six patients with cholesteryl ester transfer protein (CETP) deficiency. In these patients, the amount of LpA-I and LpA-I/A-II had increased significantly. Sixty-five percent of plasma apoA-I was associated with LpA-I/A-II, which indicated that LpA-I/A-II was predominant. The chemical composition of both LpA-I and LpA-I/A-II was characterized by increased ratios of neutral to polar lipid, compared with findings in normal subjects. Particle sizes of these lipoproteins shifted to larger diameter ranges, as compared to the size seen in normal subjects. Incubation of patients' LpA-I and LpA-I/A-II with CETP markedly corrected the chemical and physical abnormalities in these lipoproteins. Cholesterol-reducing capacities of these lipoproteins from macrophage foam cells were significantly lower than in normal controls. Cholesterol esterification rates in LpA-I, LpA-I/A-II, and plasma were significantly lower in patients than in normal controls. We propose that the structure and function of LpA-I and LpA-I/A-II are severely affected in the presence of CETP deficiency.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7616116

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  5 in total

1.  Apolipoprotein A-II alters the proteome of human lipoproteins and enhances cholesterol efflux from ABCA1.

Authors:  John T Melchior; Scott E Street; Allison B Andraski; Jeremy D Furtado; Frank M Sacks; Rebecca L Shute; Emily I Greve; Debi K Swertfeger; Hailong Li; Amy S Shah; L Jason Lu; W Sean Davidson
Journal:  J Lipid Res       Date:  2017-05-05       Impact factor: 5.922

2.  Reduced aortic lesions and elevated high density lipoprotein levels in transgenic mice overexpressing mouse apolipoprotein A-IV.

Authors:  R D Cohen; L W Castellani; J H Qiao; B J Van Lenten; A J Lusis; K Reue
Journal:  J Clin Invest       Date:  1997-04-15       Impact factor: 14.808

3.  Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

Authors:  S Zhong; D S Sharp; J S Grove; C Bruce; K Yano; J D Curb; A R Tall
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

4.  ApoA-I/A-II-HDL positively associates with apoB-lipoproteins as a potential atherogenic indicator.

Authors:  Toshimi Kido; Kazuo Kondo; Hideaki Kurata; Yoko Fujiwara; Takeyoshi Urata; Hiroshige Itakura; Shinji Yokoyama
Journal:  Lipids Health Dis       Date:  2017-11-29       Impact factor: 3.876

5.  Bioinformatic Analysis of Plasma Apolipoproteins A-I and A-II Revealed Unique Features of A-I/A-II HDL Particles in Human Plasma.

Authors:  Toshimi Kido; Hideaki Kurata; Kazuo Kondo; Hiroshige Itakura; Mitsuyo Okazaki; Takeyoshi Urata; Shinji Yokoyama
Journal:  Sci Rep       Date:  2016-08-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.